While most of the pharmacological therapies for melanoma utilize the apoptotic machinery of the cells, the available therapeutic options are limited due to the ability of melanoma cells to resist programmed cell death. Human melanoma cell lines A-375 and M186 are sensitive to ceramide-and Fas-induced cell death, while Mel-2a and M221 are resistant. We have now found that Mel-2a and M221 cells have a significantly higher ceramide/sphingosine-1-phosphate (S1P) ratio than A-375 and M186 cells. As sphingosine kinase (SphK) type 1 plays a critical role in determining the dynamic balance between the proapoptotic sphingolipid metabolite ceramide and the prosurvival S1P, we examined its role in apoptosis of melanoma cells. Increasing SphK1 expression reduced the sensitivity of A-375 melanoma cells to Fas-and ceramide-mediated apoptosis. Conversely, downregulation of SphK1 with small interfering RNA decreased the resistance of Mel-2a cells to apoptosis. Importantly, overexpression of the prosurvival protein Bcl-2 in A-375 cells markedly stimulated SphK1 expression and activity, while downregulation of Bcl-2 reduced SphK1 expression. This link between Bcl-2 and SphK1 might be an additional clue to chemotherapy resistance of malignant melanoma.
Introduction
Melanoma is largely considered to be a chemotherapy refractory tumor. The underlying molecular mechanisms for this resistance, however, have not yet been characterized (Serrone and Hersey, 1999) . Abundant evidence indicates that melanoma cells show defects at multiple levels of the apoptotic program (Satyamoorthy et al., 2001) , including altered signaling of death receptors (Thomas and Hersey, 1998) , increased levels of antiapoptotic Bcl-2 proteins (Tang et al., 1998) , overexpression of members of the inhibitor of apoptosis protein (IAP) family (Grossman et al., 1999) , as well as inactivation of effector molecules of the apoptotic signaling cascade, such as apoptosis activating factor-1 (Apaf-1) (Soengas et al., 2001) . In previous studies characterizing 11 different human melanoma cell populations, we classified melanoma cells into two subpopulations: one group was susceptible and another group was resistant to apoptotic stimuli, such as ceramide and Fas ligation (Raisova et al., 2000) . Analysis of expression of the components of the apoptotic machinery in these two subpopulations did not reveal substantial differences. However, we subsequently noted that the resistant cells had a defect in cytochrome c release as well as an increased ratio of Bcl-2 to Bax (Raisova et al., 2001) .
Numerous studies have shown that increased intracellular levels of the sphingolipid metabolite ceramide inhibit cell proliferation and enhance differentiation and apoptosis (reviewed in Jayadev and Perry and Hannun, 1998; Geilen et al., 2001) . Many anticancer drugs induce apoptosis by increasing intracellular ceramide levels (Ogretmen and Hannun, 2001 ). Ceramide-mediated clustering has been suggested to be required for CD95-death-inducing signaling complex formation (Grassme et al., 2003) . One mechanism by which cancer cells can evade anticancer drugs is by altering their metabolism of ceramide. Blocking ceramide generation (Bose et al., 1995) or its rapid removal (Xia et al., 1999; Strelow et al., 2000) or conversion to glucosylceramide (Liu et al., 1999) suppresses apoptosis.
In contrast to ceramide, its further metabolite sphingosine-1-phosphate (S1P) has been associated with cell growth and suppresses ceramide-mediated cell death (Cuvillier et al., 1996; Osawa et al., 2001) . Several growth and survival factors such as platelet-derived growth factor (PDGF), nerve growth factor (NGF), basic fibroblast growth factor (bFGF) and phorbol esters activate sphingosine kinase (SphK), the enzyme that phosphorylates sphingosine, leading to an increase in S1P levels and a concomitant decrease in ceramide levels Rius et al., 1997; Olivera et al., 1999a; Johnson et al., 2002) . Moreover, overexpression of SphK protects cells from apoptosis induced by serum withdrawal or ceramide (Olivera et al., 1999a (Olivera et al., , 2003 . Thus, the dynamic balance between ceramide and S1P can be a decisive factor in determining whether or not a cell undergoes apoptosis. Inhibitors of SphK1, such as N,N-dimethylsphingosine and L-threo-dihydrosphingosine, induce apoptosis regardless of multidrug resistance expression (Jendiroba et al., 2002) , and may provide a new strategy for the treatment of anticancer drugresistant cancers. Indeed, SphK inhibitors reduce gastric tumor growth (Endo et al., 1991) and mammary adenocarcinoma tumor growth in mice (French et al., 2003) . As SphK1 is overexpressed in a variety of solid tumors, including breast, stomach, ovary, kidney and lung, compared to normal tissues from the same patients (French et al., 2003) , it was of interest to examine its role in resistance of melanoma cells to apoptosis.
Results

Extracellular-regulated kinase (ERK)1/2 is constitutively phosphorylated in melanoma cells
Constitutive ERK phosphorylation is correlative with malignant transformation in many tumor cell lines including some melanoma cell populations (Kortylewski et al., 2001; Govindarajan et al., 2003) . Thus, it was of interest to examine ERK activation in cells, which are resistant to ceramide and agonistic activation of Fas by the CH-11 antibody (Mel-2a and M221 cells) compared to Fas and ceramide sensitive (A-375 and M186 cells). All of these melanoma cell lines showed a high basal level of ERK1/2 phosphorylation. Furthermore, ERK1/ 2 phosphorylation was not increased by the presence of serum (data not shown), suggesting that apoptosis susceptibility of melanoma cells is not correlated with ERK activation.
Ceramide-resistant melanoma cells have a higher S1P/ ceramide ratio
To examine the role of sphingolipid metabolites in the disparity in the apoptotic behavior between resistant and sensitive melanoma cells, we measured the intracellular levels of S1P and ceramide. The sensitive cell lines, A-375 and M186, had higher basal ceramide levels than the resistant cells, M221 and Mel-2a (Figure 1a ). On the other hand, only M221, not Mel-2a, displayed higher levels of S1P than the sensitive cell lines, A-375 and M186 (Figure 1b) . Since the ratio of S1P to ceramide within a cell may be crucial in determining the outcome of an apoptotic stimulus, the S1P/ceramide ratio was compared in the sensitive and resistant cells. The ratio was significantly higher in both resistant cell lines, Mel2a and M221, than in the sensitive A-375 and M186 cells (Figure 1c) , consistent with the opposite effects of ceramide and S1P on cell survival. Increases in cellular S1P protect against apoptosis induced by ceramide or FasL (Cuvillier et al., 1996; Osawa et al., 2001) . SphK, which catalyses the phosphorylation of sphingosine to S1P, is the critical enzyme that regulates intracellular levels of S1P. Therefore, we correlated S1P levels in melanoma cells with SphK activity. Indeed, SphK activity was nearly fourfold higher in Mel-2a cells than in A-375 and M186 cells. SphK activity in M221 cells was not as high but was still significantly greater than A-375 and M186 cells (Figure 2a) . Moreover, the higher SphK1 activity correlated with SphK1 protein expression as shown by Western blot analysis (Figure 2b ).
Ectopic SphK1 expression suppresses ceramide-mediated cell death
As SphK1 expression and activity were higher in ceramide-resistant Mel-2a cells than in sensitive A-375 cells and its expression suppresses ceramide-mediated cell death in other cell types (Olivera et al., 1999a (Olivera et al., , 2003 , it was of interest to determine whether overexpression of SphK1 in A-375 would induce resistance to apoptosis. To this end, we prepared A-375 cells stably overexpressing wild-type (wt) SphK1. Cells stably expressing catalytically inactive SphK1 containing a point mutation (G82D) in the ATP binding site (Pitson et al., 2000) were also isolated. As expected, cells expressing wtSphK but not catalytically inactive SphK1 had increased sphingosine phosphorylating activity (Figure 3b and c), although SphK1 protein was expressed to the same level in both cells (Figure 3a) .
Overexpression of wt-SphK1 significantly reduced cell death induced by exogenous short-chain C 6 -ceramide (N-hexanoylsphingosine) (Figure 4a ). It should be noted that treatment of cells with C 6 -ceramide resulted in a significant increase in endogenous long-chain apoptotic ceramide species (Ogretmen et al., 2002) . Similarly, expression of SphK1 significantly reduced cell death induced by agonistic Fas antibody CH-11 or by doxorubicin, although the antiapoptotic effect of SphK1 was less pronounced (Figure 4b ). In sharp contrast, overexpression of inactive SphK1 did not influence the apoptotic effects of C 6 -ceramide (Figure 4c ), CH-11 or doxorubicin (data not shown). 
Sensitization of Mel-2a cells to ceramide-mediated apoptosis by downregulation of endogenous SphK1 expression
To further investigate the role of endogenous SphK1 in ceramide resistance of Mel-2a cells, its expression was specifically reduced by small interfering RNA (siRNA). siRNA targeted against SphK1 markedly downregulated expression of both SphK1 mRNA and protein (Figure 5a and b). This downregulation was also reflected in significantly decreased SphK1 activity ( Figure 5c ). Furthermore, siSphK1 increased the sensitivity of Mel-2a cells to apoptosis induced by ceramide and CH-11 by about twofold as compared to cells treated with control siRNA (Figure 5d ).
Correlation of Bcl-2 expression and SphK1 in melanoma cells
Previously, we have demonstrated that a high Bcl-2/Bax ratio correlated with resistance of melanoma cells to apoptosis induced by ceramide or CH-11 antibody (Raisova et al., 2001) . Mel-2a cells express higher levels of both Bcl-2 ( Figure 6a ) and SphK1 ( Figure 2a ) than A-375 cells. Since both proteins are antiapoptotic, it was of interest to determine whether there is a correlation between Bcl-2 and SphK1 expression. siRNA targeted to SphK1 did not significantly affect Bcl-2 expression ( Figure 5b ). In addition, overexpression of SphK1 in A-375 cells did not change expression of Bcl-2 as determined by Western analysis (Figure 6b ). These results suggest that SphK1 does not regulate the expression of Bcl-2. However, we noticed that stably overexpressing Bcl-2 in A-375 cells caused a twofold increase in SphK1 enzymatic activity (Figure 6c ) that correlated with higher SphK1 protein expression in these cells (Figure 6d ). To further substantiate the correlation between Bcl-2 expression and SphK1 activity, we used the tetracycline/ doxycycline-inducible expression system in the apoptosis-sensitive melanoma cell line Bro . Bro-Tet-On cells transfected with a Bcl-2 expression vector under the control of the Tet promoter showed increased Bcl-2 expression after 8 and 24 h of doxycycline induction (Figure 7d ). In agreement with other reports (Zhang et al., 1996; Raisova et al., 2002) , induction of Bcl-2 in these melanoma cells significantly decreased apoptosis induced by C 6 -ceramide and CH-11 as compared to vector-transfected cells (Figure 7a and b) . In parallel with increased Bcl-2 expression, there was an increase in SphK1 expression (Figure 7d ). Moreover, this correlated with SphK1 activity that was increased after 8 and 24 h of doxycycline treatment by twofold and 2.5-fold, respectively (Figure 7c ). Nonspecific effects of doxycycline were excluded as vector-transfected Bro-Tet-On cells showed no increase in Bcl-2 (Figure 7d Recently, it has been reported that overexpression of Bcl-2 protects SphK1 from DNA damage-induced proteolysis (Taha et al., 2004) . As overexpression of Bcl-2 increases SphK1 activity (Figure 7c) , it was of interest to determine whether endogenous Bcl-2 might regulate basal SphK1 expression. Therefore, endogenous Bcl-2 was downregulated in Mel-2a cells using specific siRNA. As shown in Figure 7e , downregulation of Bcl-2 leads to a concomitant decrease in SphK1 expression and activity.
Discussion
To characterize differences between ceramide-resistant and ceramide-sensitive melanoma cells, we previously investigated the expression of several proteins involved in apoptosis. We found no differences in the expression of FLIP, caspase-8, Fas or Fas ligand (Raisova et al., 2000) . Moreover, phosphorylation of ERK1/2, which has been shown to result in increased cell survival and malignant transformation (Smalley, 2003) , cannot account for the differences in apoptosis sensitivity, as we found that it was constitutively activated in both resistant and sensitive melanoma cells. We next examined the relationship between ceramide and S1P levels in these melanoma cells. Both M221-and Mel-2a-resistant cells had lower ceramide levels than the sensitive A-375 and M186 cell lines. Consistent with the rheostat model for apoptosis (Cuvillier et al., 1996) , we found significantly higher ratios of S1P to ceramide in resistant M221 and Mel-2a cells compared to sensitive A-375 and M186 cells. Since ceramide and S1P are Equal amounts of protein from cell lysates were analyzsd by Western blotting with anti-Bcl-2 antibody or anti-hSphK1 antibody. Blots were stripped and reprobed with anti-bactin antibody to demonstrate equal loading. SphK1 activity was determined in the presence of 0.25% Triton X-100. Data are means7s.d. of triplicate determinations from three independent experiments. *Po0.05 by t-test; # Po0.05 by ANOVA; NS, not significant Bcl-2 regulates sphingosine kinase M Bektas et al interconvertable sphingolipids, and S1P may suppress ceramide-mediated apoptosis, it is possible that resistant melanoma cells are protected from apoptosis by increased SphK activity, higher S1P levels and, conversely, lower ceramide levels. In support of this hypothesis, we found higher SphK1 activity in both Mel-2a and M221. Moreover, if S1P levels are critically important for survival of melanoma cells, increased expression of SphK1 should affect the apoptotic sensitivity. In agreement, overexpression of wt, but not catalytically inactive mutant SphK1, increased resistance of A-375 melanoma cells to short-chain ceramide-, as well as to CH-11-and doxorubicin-induced apoptosis. The cytoprotective effect of SphK1 overexpression on ceramide-mediated cell death was more pronounced than on Fas-or doxorubicin-induced apoptosis, likely due to alternative death signaling pathways of Fas and doxorubicin, which do not necessarily involve ceramide or ceramide metabolites (Gewirtz, 1999; Peter and Krammer, 2003) . In further support of the decisive role of SphK1, downregulation of SphK1 expression by treatment with specific siRNA rendered ceramideresistant Mel-2a cells sensitive to ceramide-and Fasinduced cell death.
It was previously suggested that the different apoptotic responses of Mel-2a and A-375 melanoma cells could be due to differences in their Bcl-2/Bax ratios (Raisova et al., 2001) , as ceramide-resistant Mel-2a cells expressed significantly higher levels of Bcl-2 than the sensitive A-375 cells, and Bcl-2 overexpression reverses the ceramide-sensitive phenotype of A-375 (Raisova et al., 2001) . In the present study, we found that the disparity in apoptosis not only correlated with Bcl-2 expression but also with pronounced differences in SphK1 expression and activity. As both Bcl-2 and SphK1 are antiapoptotic, it was of interest to determine whether their expression was linked. There was a twofold increase in SphK1 activity in A-375 cells stably overexpressing Bcl-2 compared to naı¨ve A-375 cells. To rule out possible clonal or compensatory effects, we used Tet-On Bro melanoma cells in which Bcl-2 expression was induced by doxycycline. SphK1 activity and expression were similarly increased as a consequence of Bcl-2 induction. On the other hand, overexpression of SphK1 in A-375 cells had no effect on Bcl-2 expression, indicating that Bcl-2 might be upstream of SphK1. Interestingly, overexpression of Bcl-2 or failure to upregulate p53 MOLT-4 leukemia cells following DNA damage induced by actinomycin D inhibits the activation of proteases and, subsequently, prevents SphK1 proteolysis (Taha et al., 2004) . To explore the potential role of endogenous Bcl-2 in the regulation of SphK1 expression, Bcl-2 was specifically downregulated with siRNA. This resulted in a reduction of endogenous SphK1 activity and protein, further supporting a role for Bcl-2 in regulating SphK1 expression.
To date, not much is known about how Bcl-2 might influence gene expression. Recently, it has been reported that Bcl-2 overexpression increases the expression of the angiogenesis factor vascular endothelial growth factor (VEGF) in human melanoma cells via HIF-1 (hypoxiainducible factor 1) (Iervolino et al., 2002) . VEGFinduced ERK activation was also shown to be mediated by SphK in T24 bladder tumor cells and in HUVEC cells (Shu et al., 2002) . The activation of SphK is dependent on protein kinase C as shown in various cell types (Buehrer et al., 1996; Johnson et al., 2002) . It is therefore tempting to speculate that in melanoma cells Bcl-2 might activate SphK via VEGF upregulation. In addition, the transcription factor NF-kB has been linked to Bcl-2 expression in MCF7 ADR cells (Ricca et al., 2000) . NF-kB regulates the expression of numerous genes important for cell survival, tumor progression and invasion (Bours et al., 2000) , and constitutive NF-kB activity has been associated with tumor development and progression (Yamamoto and Gaynor, 2001 ). The BH4 domain of Bcl-2 has been shown to be crucial for the activation of NF-kB and, interestingly, this domain has also been described to interact with several other signaling molecules such as calcineurin and raf-1 (Shibasaki et al., 1997) . Further studies are needed to shed light on the mechanism of Bcl-2-induced SphK activation.
In conclusion, in this study, we demonstrate the involvement of SphK1 in the resistance of melanoma cells to apoptotic stimuli. Furthermore, we show that inhibition of ceramide-induced apoptosis by Bcl-2 may at least in part result from increased SphK1 expression and activity. Targeting SphK1 might provide additional therapeutic benefits for treatment of drug-resistant melanoma.
Materials and methods
Materials
The agonistic anti-CD95/Fas monoclonal antibody (clone CH-11) was purchased from Chemicon (Hofheim, Germany). C 6 -ceramide was purchased from Biotrend (Cologne, Germany) and dissolved in ethanol to a final concentration of 25 mM. pEGFP-neo was purchased from Clontech (Palo Alto, CA, USA). Geneticin (G418) was from Life Technologies (Karlsruhe, Germany). Doxorubicin was provided by Sigma (Munich, Germany). Sphingosine was from Biomol (Hamburg, Germany). [g-32 P]ATP (3000 Ci/mmol) was purchased from Amersham (Arlington Heights, IL, USA). High-performance TLC plates were purchased from EM Science (Gibbstown, NJ, USA). Bisbenzimide hydrochloride (Hoechst 33258) and recombinant Escherichia coli diacylglycerol kinase were from Calbiochem (La Jolla, CA, USA).
Melanoma cell culture
M186 and M221 cells were obtained from patients with histologically confirmed metastatic melanoma by surgical intervention. A-375 and Bro cells are established melanoma cell lines originating from primary human tumors (Giard et al., 1973; Lockshin et al., 1985) , whereas Mel-2a originated from metastasis (Bruggen et al., 1981) . Melanoma cell lines were grown in Dulbecco's modified Eagle's medium (Sigma) supplemented with 10% fetal bovine serum (Biochrom, Berlin, Germany), 100 U/ml penicillin and 100 mg/ ml streptomycin.
Transfection
A-375 cells were transfected with pEGFP-N1 vector (Clontech) containing the cDNA for green fluorescent protein (GFP) alone or with a plasmid containing either wt-SphK1 or catalytically inactive SphK1 (Pitson et al., 2000) fused to GFP at its C-terminus. Transfection was performed using Lipofectamine (Invitrogen) according to the manufacturer's protocol. After 2 days, cells were transferred into medium containing 1 mg/ml G418. After 2-3 weeks, green cells were sorted with an EPICS 753 argon laser flow cytometer (Beckman Coulter Epics Elite). The construction of the mouse Bcl-2 expression plasmid based on pIRES (Clontech) has been reported previously and has been shown to be functional in A-375 cells (Raisova et al., 2002) . Tetracycline/doxycycline-inducible BroTet-On melanoma cells have been described previously . We have subcloned a full-length cDNA copy of murine Bcl-2 into EcoRI and XbaI sites of pTRE1 (Clontech, Palo Alto, CA, USA). The construct pTRE-Bcl2 was then transfected into the teracycline-inducible Tet-On melanoma cell line . A stably transfected cell clone (Bro-Bcl-2) was obtained by limited dilution in microtiter plates and was continuously cultured under antibiotic pressure (geneticin, hygromycin).
SphK1 expression was downregulated with sequence-specific siRNA. siRNA for human SphK1 (sense 5 0 -GGG CAA GGC CUU GCA GCU C; antisense 5 0 -GAG CUG CAA GGC CUU GCC C) and the control siRNA were obtained from Xeragon-Qiagen (Birmingham, AL, USA). Specificity of the sequence was confirmed by the Blast program. siRNA for human Bcl-2 (cat. #M-003307-010) and control siRNA (cat. #D-001210-01) were purchased from Dharmacon (Lafayette, CO, USA). Mel-2a cells were seeded into six-well dishes at 4 Â 10 5 cells/well. After 24 h, cells were transfected for 3 h with siRNA using OligofectAMINE (Invitrogen) as recommended by the manufacturer. After 48 h, cells were treated as indicated in figure legends.
Western blot analysis
Cells were harvested in buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 20 mM orthovanadate, 10 mM pyrophosphate, 100 mM NaF, 10 mM EDTA, 1% Triton X-100, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml pepstatin A, 10 mg/ml aprotinin and 10 mg/ml leupeptin. Equal amounts of protein were separated by SDS-PAGE. Proteins were transferred onto a nitrocellulose membrane and probed with specific antibodies as follows: mouse monoclonal antimouse Bcl-2 (100/D5, Novocastra, Dossenheim, Germany), mouse monoclonal anti-human Bcl-2 (C-2, Santa Cruz, Heidelberg, Germany), rabbit polyclonal anti-SphK antibody, polyclonal phospho-ERK1/2 (New England Biolabs, Frankfurt, Germany), polyclonal antibodies against ERK2 (Santa Cruz Biotech., Santa Cruz, CA, USA), mouse monoclonal anti-b-actin (Sigma, Munich, Germany) and anti-b-tubulin (Santa Cruz Biotech.). Primary antibodies were labeled with goat-anti-mouse IgG or with goat-anti-rabbit IgG conjugated with horseradish peroxidase (Dako, Hamburg, Germany). Immunocomplexes were visualized by enhanced chemiluminescence with Super Signal West Pico reagent from Pierce (Weiskirchen, Germany).
Cell death assay
Cell death was measured with the Cell Death Detection ELISA PLUS kit (Roche Diagnostics), which determines cytoplasmic histone-associated DNA fragments (mononucleosomes and oligonucleosomes) as described previously (Wieder et al., 1998) . In some experiments, apoptotic cell death was measured by staining cell nuclei with the Hoechst dye bisbenzimide (Olivera et al., 1999b) and apoptotic cells were distinguished by condensed, fragmented nuclear regions.
RT-PCR
Total RNA was isolated from cells with RNAeasy (Qiagen, Valencia, CA, USA). RNA was reverse transcribed with Superscript II (Life Technologies, Gaithersburg, MD, USA). The following specific primers were used to amplify hSphK1: forward, 5 0 -ATC CAG AAG CCC CTG TGT AGC CTC C-3 0 ; reverse, 5 0 -GCA GCA AAC ATC TCA CTG CCC AGG T-3 0 .
SphK activity
SphK1 activity was measured as described previously (Olivera and Spiegel, 1998) . SphK1 activity is optimal under conditions of low salt and 0.25% Triton X-100. Under these conditions, SphK2 activity is negligible (Liu et al., 2000) .
Measurement of S1P
S1P was measured as described previously with some modifications (Edsall and Spiegel, 1999; Edsall et al., 2000) . Cells were washed with PBS and scraped in 1 ml of methanol. Lipids were extracted by adding 2 ml chloroform/1 M NaCl (1 : 1, v/v) and 100 ml 3 N NaOH, and phases were separated. The basic aqueous phase containing S1P, devoid of sphingosine and the majority of phospholipids, was transferred onto a siliconized glass tube. The organic phases were re-extracted with 1 ml methanol/1 M NaCl (1 : 1, v/v) plus 50 ml 3 N NaOH, and the aqueous fractions were combined. To the aqueous fraction of lipid extracts (2 ml total) was added 450 ml of the following buffer: 200 mM Tris-HCl (pH 7.4), 75 mM MgCl 2 in 1.2 M glycine buffer (pH 9.0) and 50 U of alkaline phosphatase. Samples were incubated at 371C for 30 min. To terminate the reactions, 50 ml conc. HCl was added and lipids were extracted twice with 1.5 ml CHCl 3 . Pooled organic fractions were dried under nitrogen in siliconized glass tubes and resuspended in 180 ml of SphK buffer containing 0.25% Triton X-100 and S1P measured as described previously (Olivera and Spiegel, 1998) .
Measurement of ceramide
Lipids were extracted and mass amounts of ceramide in cellular extracts measured by the DAG kinase enzymatic method as described (Toman et al., 2002) .
Statistical analysis
Statistical significance was determined using two-tailed Student's t-test or a one-way analysis of variance (ANOVA) with a Tukey post hoc and Po0.05 was considered significant.
Abbreviations IAP, inhibitor of apoptosis protein; S1P, sphingosine-1-phosphate; SphK, sphingosine kinase; ERK, extracellular regulated kinase; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; NGF, nerve growth factor; bFGF, basic fibroblast growth factor; Apaf-1, apoptosis-activating factor-1.
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